1Smith BH, Torrance N. Epidemiology of neuro- pathic pain and its impact on quality of life. Curr Pain Headache Rep, 2012, 16:191 - 198.
2Zang Y, Xin W J, Pang RE et al. Upregulation of Navl.3 channel induced by rrTNF in cultured adult rat DRG neurons via p38MAPK and JNK path- ways. Chin J Physiol, 2011, 54:241 - 246.
3Milligan ED, Watkins LR.Pathological and protec- tive roles of glia in chronic pain. Nat Rev Neuro- sci, 2009, 10:23 - 36.
4Keohr G. NMDA receptor function:subunit com- position versus spatial distribution.Cell Tissue Res, 2006, 326:439 - 446.
5Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans, 2009, 37:1147 - 1160.
6Zhou HY, Chen SR, Pan HL, et al. Targeting N- methyl-D-aspartate receptors for treatment of neu- ropathic pain. Expert Rev Clin Pharmacol, 2011, 4: 379 - 388.
7Truin M, Janssen SP, van KleefM, et al. Successful pain relief in non-responders to spinal cord stimu- lation: The combined use of ketamine and spinal cord stimulation. Eur J Pain, 2011, 15: 1049e1- 1049e9.
8Prommer EE.Ketamine for pain: an update of uses in palliative care. J Palliat Med, 2012, 15:474-483.
9Gao X, Kim HK, Chung JM, et al. Enhancement of NMDA receptor phosphorylation of the spinal dorsal horn and nucleus gracilis neurons in neu- ropathic rats. Pain, 2005, 116:62 - 72.
10Kim HW, Roh DH, Yoon SY, et al. Activation of the spinal sigma-1 receptor enhances NMDA- induced pain via PKC- and PKA-dependent phosphorylation of the NRlsubunit in mice.Br J Pharmacol, 2008, 154:1125 - 1134.
3Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post - herpetic neuralgia and painful diabetic neuropathy [ J ]. CNS Drugs, 2008, 22 ( 5 ) : 417.
4Kamiya H, Asano Y, Shiraki K, et al. Herpes roster and its prevention[J]. Kansenshogaku Zasshi, 2010, 84(6) :694.
